Department of Gastroenterology, Adelaide and Meath Hospital incorporating the National Children's Hospital/Trinity College Dublin, Dublin, Ireland.
Helicobacter. 2011 Sep;16 Suppl 1:53-8. doi: 10.1111/j.1523-5378.2011.00881.x.
This article reviews the literature published pertaining to Helicobacter pylori eradication over the last year. The general perception among clinicians and academics engaged in research on H. pylori has been that eradication rates for first-line therapies are falling, although some data published this year have cast doubt on this. The studies published this year have therefore focussed on developing alternative strategies for the first-line eradication of H. pylori. In this regard, clear evidence now exists that both levofloxacin and bismuth are viable options for first-line therapy. The sequential and "concomitant" regimes have also been studied in new settings and may have a role in future algorithms also. In addition, data have emerged that the probiotic Saccharomyces boulardii may be a useful adjunct to antibiotic therapy. Other studies promote individualized therapies based on host polymorphisms, age, and other such demographic factors.
本文回顾了过去一年中发表的有关幽门螺杆菌根除的文献。临床医生和从事幽门螺杆菌研究的学者普遍认为，一线治疗的根除率正在下降，但今年发表的一些数据对此提出了质疑。今年发表的研究因此侧重于为幽门螺杆菌的一线根除开发替代策略。在这方面，现在有明确的证据表明左氧氟沙星和铋都是一线治疗的可行选择。序贯和“同时”疗法也在新的环境中进行了研究，未来的算法中也可能有其作用。此外，有数据表明，益生菌布拉氏酵母菌可能是抗生素治疗的有用辅助手段。其他研究则根据宿主多态性、年龄和其他人口统计学因素提出了个体化治疗方案。
